IMPACT on the clinical course. As Dexrazoxane 149003-01-0 is the case for the great treatment on the reactivity of t is the platelets in patients prescribed aspirin because ISNO to help individualize timely advice on the use of platelet function or genetic tests on such therapy. Check Gauging Responsiveness With an impact test now for Thrombosis and safety study, no evidence found of reduced kardiovaskul Re events or stent thrombosis when clopidogrel was given a double dose to patients with Thrombozytenreaktivit t rest after implantation of drug-eluting stent, despite aspirin usual dose and clopidogrel. 199 Several studies are currently underway to test the hypothesis that the adjustment of therapy in response to the test results of platelet function k Can improve clinical outcomes. 200 Studies are also underway to identify the potential benefits of pets a genotype-run strategy for the management of patients at risk for poor outcomes assessed, either because they have had an adverse event or because of the high risk features, such as diabetes mellitus, chronic kidney disease, or angiographic high-risk features. 198 4.2.3 Efficiency and Safety: The clinical development of clopidogrel was similar ungew because the phase 2 studies were Descr nkt and was its agreement to a single large s Phase 3 trial, the effi ciency in comparison based and safety of clopidogrel with that of aspirin. The 201 aspirin vs. clopidogrel in patients at risk for isch chemical events study involved three groups of patients with increased risk for recurrent isch htem chemical events, each group 6400 patients Those recently a stroke, those who suffered a myocardial infarction of infarction, and those of symptomatic peripheral arterial occlusive disease. Compared to aspirin in the general population of patients at high risk CAPRIE 19.185, clopidogrel reduced the relative risk of myocardial infarction, isch Ischemic stroke or vascular Rer death by 8.7% and absolute risk of 0.51%. Both clopidogrel and medium-sized low-dose aspirin treatment was well tolerated buy Streptozotocin well tolerated in the CAPRIE study. 201 The rate of premature closure of the study drug because of side effects was 12% in both groups. Similarly, the incidence of bleeding 9.3% in both groups. No excess neutropenia was found in the clopidogrel group, and the incidence of thrombocytopenia was Similar in the clopidogrel and aspirin. Based on these fi ndings, clopidogrel has been approved for the reduction kardiovaskul Rer events in patients with stroke, recent myocardial infarction or established peripheral arterial occlusive disease. TTP is a rare but can occur after initiation of clopidogrel if TTP occurs, its occurrence is usually within 2 weeks after starting treatment. 202 Because clopidogrel and aspirin affect distinct and erg Complementary pathways of platelet activation, the combined therapy was evaluated in clinical environments with high risk. 203 208 208 CURE study randomized patients with ACS without ST segment elevationwho 12.562 presented within 24 hours of onset of symptoms My additionally to clopidogrel or placebo Tzlich to receive aspirin for 3 to 12 months. After a mean treatment duration of 9 months, the most important result was observed in 9.3% of patients in the clopidogrel group and 11.4% in the placebo group. If the receiver was singer of clopidogrel within 30 days of RST fi apparently ran.